Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Epigenetic Silencing of THY1 Tracks the Acquisition of the Notch1-EGFR Signaling in a Xenograft Model of CD44+/CD24low/CD90+ Myoepithelial Cells.

Montanari M, Carbone MR, Coppola L, Giuliano M, Arpino G, Lauria R, Nardone A, Leccia F, Trivedi MV, Garbi C, Bianco R, Avvedimento EV, De Placido S, Veneziani BM.

Mol Cancer Res. 2018 Sep 21. doi: 10.1158/1541-7786.MCR-17-0324. [Epub ahead of print]

PMID:
30242055
2.

Exploring the molecular aspects associated with testicular germ cell tumors: a review.

Facchini G, Rossetti S, Cavaliere C, D'Aniello C, Di Franco R, Iovane G, Grimaldi G, Piscitelli R, Muto P, Botti G, Perdonà S, Veneziani BM, Berretta M, Montanari M.

Oncotarget. 2017 Nov 3;9(1):1365-1379. doi: 10.18632/oncotarget.22373. eCollection 2018 Jan 2. Review.

3.

Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results.

De Placido S, Giuliano M, Schettini F, Von Arx C, Buono G, Riccardi F, Cianniello D, Caputo R, Puglisi F, Bonotto M, Fabi A, Bilancia D, Ciccarese M, Lorusso V, Michelotti A, Bruzzese D, Veneziani BM, Locci M, De Laurentiis M, Arpino G.

Breast. 2018 Apr;38:86-91. doi: 10.1016/j.breast.2017.12.012. Epub 2018 Jan 4.

PMID:
29287189
4.

Alterations of autophagy in the peripheral neuropathy Charcot-Marie-Tooth type 2B.

Colecchia D, Stasi M, Leonardi M, Manganelli F, Nolano M, Veneziani BM, Santoro L, Eskelinen EL, Chiariello M, Bucci C.

Autophagy. 2018;14(6):930-941. doi: 10.1080/15548627.2017.1388475. Epub 2018 May 4.

5.

Correction: Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences.

Quagliariello V, Rossetti S, Cavaliere C, Di Palo R, Lamantia E, Castaldo L, Nocerino F, Ametrano G, Cappuccio F, Malzone G, Montanari M, Vanacore D, Romano FJ, Piscitelli R, Iovane G, Pepe MF, Berretta M, D'Aniello C, Perdonà S, Muto P, Botti G, Ciliberto G, Veneziani BM, De Falco F, Maiolino P, Caraglia M, Montella M, Iaffaioli RV, Facchini G.

Oncotarget. 2017 Sep 22;8(37):62816. doi: 10.18632/oncotarget.20631. eCollection 2017 Sep 22.

6.

Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.

Mauro CD, Pesapane A, Formisano L, Rosa R, D'Amato V, Ciciola P, Servetto A, Marciano R, Orsini RC, Monteleone F, Zambrano N, Fontanini G, Servadio A, Pignataro G, Grumetto L, Lavecchia A, Bruzzese D, Iaccarino A, Troncone G, Veneziani BM, Montuori N, Placido S, Bianco R.

Sci Rep. 2017 Aug 24;7(1):9388. doi: 10.1038/s41598-017-10062-1.

7.

Micrornas in prostate cancer: an overview.

Vanacore D, Boccellino M, Rossetti S, Cavaliere C, D'Aniello C, Di Franco R, Romano FJ, Montanari M, La Mantia E, Piscitelli R, Nocerino F, Cappuccio F, Grimaldi G, Izzo A, Castaldo L, Pepe MF, Malzone MG, Iovane G, Ametrano G, Stiuso P, Quagliuolo L, Barberio D, Perdonà S, Muto P, Montella M, Maiolino P, Veneziani BM, Botti G, Caraglia M, Facchini G.

Oncotarget. 2017 Jul 25;8(30):50240-50251. doi: 10.18632/oncotarget.16933. Review.

8.

Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers.

Di Mauro C, Rosa R, D'Amato V, Ciciola P, Servetto A, Marciano R, Orsini RC, Formisano L, De Falco S, Cicatiello V, Di Bonito M, Cantile M, Collina F, Chambery A, Veneziani BM, De Placido S, Bianco R.

Br J Cancer. 2017 May 23;116(11):1425-1435. doi: 10.1038/bjc.2017.116. Epub 2017 Apr 25.

9.

Epithelial-mesenchymal transition in prostate cancer: an overview.

Montanari M, Rossetti S, Cavaliere C, D'Aniello C, Malzone MG, Vanacore D, Di Franco R, La Mantia E, Iovane G, Piscitelli R, Muscariello R, Berretta M, Perdonà S, Muto P, Botti G, Bianchi AAM, Veneziani BM, Facchini G.

Oncotarget. 2017 May 23;8(21):35376-35389. doi: 10.18632/oncotarget.15686. Review.

10.

Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences.

Quagliariello V, Rossetti S, Cavaliere C, Di Palo R, Lamantia E, Castaldo L, Nocerino F, Ametrano G, Cappuccio F, Malzone G, Montanari M, Vanacore D, Romano FJ, Piscitelli R, Iovane G, Pepe MF, Berretta M, D'Aniello C, Perdonà S, Muto P, Botti G, Ciliberto G, Veneziani BM, De Falco F, Maiolino P, Caraglia M, Montella M, Iaffaioli RV, Facchini G.

Oncotarget. 2017 May 2;8(18):30606-30616. doi: 10.18632/oncotarget.16725. Review. Erratum in: Oncotarget. 2017 Sep 22;8(37):62816.

11.

Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review.

Romano FJ, Rossetti S, Conteduca V, Schepisi G, Cavaliere C, Di Franco R, La Mantia E, Castaldo L, Nocerino F, Ametrano G, Cappuccio F, Malzone G, Montanari M, Vanacore D, Quagliariello V, Piscitelli R, Pepe MF, Berretta M, D'Aniello C, Perdonà S, Muto P, Botti G, Ciliberto G, Veneziani BM, De Falco F, Maiolino P, Caraglia M, Montella M, De Giorgi U, Facchini G.

Oncotarget. 2016 Dec 20;7(51):85641-85649. doi: 10.18632/oncotarget.13063. Review.

12.

Everolimus induces Met inactivation by disrupting the FKBP12/Met complex.

Raimondo L, D'Amato V, Servetto A, Rosa R, Marciano R, Formisano L, Di Mauro C, Orsini RC, Cascetta P, Ciciola P, De Maio AP, Di Renzo MF, Cosconati S, Bruno A, Randazzo A, Napolitano F, Montuori N, Veneziani BM, De Placido S, Bianco R.

Oncotarget. 2016 Jun 28;7(26):40073-40084. doi: 10.18632/oncotarget.9484.

13.

Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy.

Arpino G, De Angelis C, Buono G, Colao A, Giuliano M, Malgieri S, Cicala S, De Laurentiis M, Accurso A, Crispo A, Limite G, Lauria R, Veneziani BM, Forestieri V, Bruzzese D, De Placido S.

Breast Cancer Res Treat. 2015 Nov;154(1):127-32. doi: 10.1007/s10549-015-3586-x. Epub 2015 Sep 30.

14.

Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.

Formisano L, D'Amato V, Servetto A, Brillante S, Raimondo L, Di Mauro C, Marciano R, Orsini RC, Cosconati S, Randazzo A, Parsons SJ, Montuori N, Veneziani BM, De Placido S, Rosa R, Bianco R.

Oncotarget. 2015 Sep 22;6(28):26090-103. doi: 10.18632/oncotarget.4636.

15.

Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.

Giuliano M, Herrera S, Christiny P, Shaw C, Creighton CJ, Mitchell T, Bhat R, Zhang X, Mao S, Dobrolecki LE, Al-rawi A, Chen F, Veneziani BM, Zhang XH, Hilsenbeck SG, Contreras A, Gutierrez C, Jeselsohn RM, Rimawi MF, Osborne CK, Lewis MT, Schiff R, Trivedi MV.

Breast Cancer Res. 2015 Jan 9;17:3. doi: 10.1186/s13058-014-0508-5.

16.

Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.

D'Amato C, Rosa R, Marciano R, D'Amato V, Formisano L, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fulciniti F, Cipolletta A, Bianco C, Ciardiello F, Veneziani BM, De Placido S, Bianco R.

Br J Cancer. 2014 Sep 9;111(6):1168-79. doi: 10.1038/bjc.2014.421. Epub 2014 Aug 5.

17.

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.

D'Amato V, Rosa R, D'Amato C, Formisano L, Marciano R, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fusciello C, Veneziani BM, De Placido S, Bianco R.

Br J Cancer. 2014 Jun 10;110(12):2887-95. doi: 10.1038/bjc.2014.241. Epub 2014 May 13.

18.

Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma.

Rosa R, Damiano V, Formisano L, Nappi L, Marciano R, Veneziani BM, De Placido S, Bianco R.

Oncoimmunology. 2013 Aug 1;2(8):e25123. Epub 2013 May 28.

19.

Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.

Damiano V, Rosa R, Formisano L, Nappi L, Gelardi T, Marciano R, Cozzolino I, Troncone G, Agrawal S, Veneziani BM, De Placido S, Bianco R, Tortora G.

Br J Cancer. 2013 Apr 30;108(8):1616-23. doi: 10.1038/bjc.2013.153. Epub 2013 Apr 9.

20.

Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.

Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marfè G, Del Vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, Veneziani BM, Troncone G, De Placido S, Bianco R.

Clin Cancer Res. 2013 Jan 1;19(1):138-47. doi: 10.1158/1078-0432.CCR-12-1050. Epub 2012 Nov 19.

21.

Cytometric and biochemical characterization of human breast cancer cells reveals heterogeneous myoepithelial phenotypes.

Leccia F, Nardone A, Corvigno S, Vecchio LD, De Placido S, Salvatore F, Veneziani BM.

Cytometry A. 2012 Nov;81(11):960-72. doi: 10.1002/cyto.a.22095. Epub 2012 Jul 12.

22.

Issues of banking breast cancer cells to generate mammospheres.

Veneziani BM, De Placido S.

Cell Tissue Bank. 2013 Jun;14(2):153-8. doi: 10.1007/s10561-012-9320-6. Epub 2012 Jun 6. Review.

PMID:
22669494
23.

Cells derived from normal or cancer breast tissue exhibit different growth properties when deprived of arginine.

Chiaviello A, Paciello I, Veneziani BM, Palumbo G, Aloj SM.

Med Oncol. 2012 Dec;29(4):2543-51. doi: 10.1007/s12032-011-0130-7. Epub 2011 Dec 20.

PMID:
22183716
24.

Long-term cultures of stem/progenitor cells from lobular and ductal breast carcinomas under non-adherent conditions.

Nardone A, Corvigno S, Brescia A, D'Andrea D, Limite G, Veneziani BM.

Cytotechnology. 2011 Jan;63(1):67-80. doi: 10.1007/s10616-010-9328-3. Epub 2010 Dec 28.

25.

Combined inhibitory effect of formestane and herceptin on a subpopulation of CD44+/CD24low breast cancer cells.

Cavaliere C, Corvigno S, Galgani M, Limite G, Nardone A, Veneziani BM.

Cancer Sci. 2010 Jul;101(7):1661-9. doi: 10.1111/j.1349-7006.2010.01593.x. Epub 2010 Apr 19.

26.

A banking strategy toward customized therapy in breast cancer.

Nardone A, Cavaliere C, Corvigno S, Limite G, De Placido S, Veneziani BM.

Cell Tissue Bank. 2009 Nov;10(4):301-8. doi: 10.1007/s10561-009-9124-5. Epub 2009 Jan 29.

PMID:
19184530
27.

In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches.

Veneziani BM, Criniti V, Cavaliere C, Corvigno S, Nardone A, Picarelli S, Tortora G, Ciardiello F, Limite G, De Placido S.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3091-100.

28.

Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.

Morelli MP, Cascone T, Troiani T, Tuccillo C, Bianco R, Normanno N, Romano M, Veneziani BM, Fontanini G, Eckhardt SG, De Pacido S, Tortora G, Ciardiello F.

J Cell Physiol. 2006 Aug;208(2):344-53.

PMID:
16688779
30.

Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.

Melisi D, Caputo R, Damiano V, Bianco R, Veneziani BM, Bianco AR, De Placido S, Ciardiello F, Tortora G.

Endocr Relat Cancer. 2005 Dec;12(4):1051-8.

PMID:
16322342
31.

Photodynamic therapy with indocyanine green complements and enhances low-dose cisplatin cytotoxicity in MCF-7 breast cancer cells.

Crescenzi E, Varriale L, Iovino M, Chiaviello A, Veneziani BM, Palumbo G.

Mol Cancer Ther. 2004 May;3(5):537-44.

32.

Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.

Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F.

Clin Cancer Res. 2003 Apr;9(4):1566-72.

33.

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G.

Clin Cancer Res. 2003 Apr;9(4):1546-56.

34.

Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.

Tortora G, Caputo R, Damiano V, Caputo R, Troiani T, Veneziani BM, De Placido S, Bianco AR, Zangemeister-Wittke U, Ciardiello F.

Clin Cancer Res. 2003 Feb;9(2):866-71.

35.

Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).

Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S, Bianco AR, Ciardiello F.

Clin Cancer Res. 2002 Oct;8(10):3250-8.

37.
38.

The disulfide bond pattern between fragments obtained by the limited proteolysis of bovine thyroglobulin.

Veneziani BM, Giallauria F, Gentile F.

Biochimie. 1999 May;81(5):517-25.

PMID:
10403184
39.

Sustained versus transient cyclic AMP intracellular levels: effect on thyrotropin-dependent growth of thyroid cells.

Villone G, De Amicis F, Veneziani BM, Salzano S, Di Carlo A, Tramontano D.

Cell Growth Differ. 1997 Nov;8(11):1181-8.

40.

Polyacrylamide gel electrophoresis in discontinuous transverse urea-gradient gels.

Gentile F, Veneziani BM, Sellitto C.

Anal Biochem. 1997 Jan 15;244(2):228-32.

PMID:
9025938
41.

Expression of the soluble lectin L-14 gene is induced by TSH in thyroid cells and suppressed by retinoic acid in transformed neural cells.

Chiariotti L, Benvenuto G, Salvatore P, Veneziani BM, Villone G, Fusco A, Russo T, Bruni CB.

Biochem Biophys Res Commun. 1994 Mar 15;199(2):540-6.

PMID:
8135794
42.

In the thyroid cells proliferation, differentiated and metabolic functions are under the control of different steps of the cyclic AMP cascade.

Villone G, Veneziani BM, Picone R, De Amicis F, Perrotti N, Tramontano D.

Mol Cell Endocrinol. 1993 Sep;95(1-2):85-93.

PMID:
8243811
43.

Transfected insulin-like growth factor II modulates the mitogenic response of rat thyrocytes in culture.

Veneziani BM, Di Marino C, Salvatore P, Villone G, Perrotti N, Frunzio R, Tramontano D.

Mol Cell Endocrinol. 1992 Jul;86(1-2):11-20.

PMID:
1511776
44.

The tissue-specific pathways regulating cell proliferation are inherited independently in somatic hybrid between thyroid and liver cells.

Veneziani BM, Villone G, Romano R, Di Carlo A, Garbi C, Tramontano D.

J Cell Biol. 1990 Dec;111(6 Pt 1):2703-11.

46.

Iodine inhibits the proliferation of rat thyroid cells in culture.

Tramontano D, Veneziani BM, Lombardi A, Villone G, Ingbar SH.

Endocrinology. 1989 Aug;125(2):984-92.

PMID:
2546752
47.

Independent and interactive effects of tetradecanoyl phorbol acetate on growth and differentiated functions of FRTL5 cells.

Lombardi A, Veneziani BM, Tramontano D, Ingbar SH.

Endocrinology. 1988 Sep;123(3):1544-52.

PMID:
2841099
48.
49.

TSH-EGF cooperation in the FRTL5 thyroid cell growth stimulation.

Veneziani BM, Tramontano D, Ambesi-Impiombato FS.

Prog Clin Biol Res. 1986;226:277-85. No abstract available.

PMID:
3492717

Supplemental Content

Loading ...
Support Center